Concepedia

Susan Ashwell

SA

Statistics

Publications

13

Citations

1K

H-Index

12

Active since

1989

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

Princeton University

Forma Therapeutics (United States)

Memorial Sloan Kettering Cancer Center

Susan Ashwell is an author at AstraZeneca (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

1989–2020

13

Publications

13

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Sonya Zabludoff, Chun Deng, Michael Grondine et al. · Molecular Cancer Therapeutics · 2008 · 410 citations · Full text

, , +17

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor

Justin A. Caravella, Jian Lin, R. Bruce Diebold et al. · Journal of Medicinal Chemistry · 2020 · 144 citations · Full text

, , +15

Identification of Compounds with Nanomolar Binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening

Paul D. Lyne, Peter W. Kenny, David A. Cosgrove et al. · Journal of Medicinal Chemistry · 2004 · 112 citations · Full text

, , +17

Discovery of Checkpoint Kinase Inhibitor (<i>S</i>)-5-(3-Fluorophenyl)-<i>N</i>-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas

Vibha Oza, Susan Ashwell, Lynsie Almeida et al. · Journal of Medicinal Chemistry · 2012 · 70 citations · Full text

, , +16

Inhibitors of checkpoint kinases: from discovery to the clinic.

James W. Janetka, Susan Ashwell, Sonya Zabludoff et al. · PubMed · 2007 · 65 citations

, , +17

1–5 of 13